Learn how VENCLEXTA works
for CLL/SLL

Actor portrayals.

VENCLEXTA is not a chemotherapy

It is a pill that works differently than other treatments for adults with CLL or SLL.

How VENCLEXTA treats CLL/SLL within your body

Normal Cell

When normal cells are old or damaged, your body triggers them to self‑destruct. This process is called apoptosis (ay‑pop‑toh‑sis).

Cancer cell

In certain types of cancer, there is too much of a protein called BCL‑2. BCL‑2 blocks the cell from triggering apoptosis. When this happens, cancer cells do not self‑destruct as they naturally would, and they build up in the body.

VENCLEXTA

VENCLEXTA targets BCL‑2 proteins and attaches to them. When VENCLEXTA is attached to these proteins, it helps to restore the process of apoptosis, allowing these cells to self‑destruct.

VENCLEXTA combination therapy

Your healthcare provider may prescribe VENCLEXTA to be used in combination with another therapy.

VENCLEXTA + acalabrutinibTwice-daily acalabrutinib, a type of Bruton tyrosine kinase inhibitor (BTKi), is taken orally with daily VENCLEXTA.

BTKis are a type of targeted therapy used to fight CLL or SLL. In CLL, the pathway that B-cells use to grow becomes overactive, causing these cells to multiply too much and avoid dying when they should. BTKis work by blocking a protein called BTK that contributes to the growth and spread of CLL cancer cells (and some healthy cells) to slow the progression of CLL.

VENCLEXTA + obinutuzumab or rituximab

GAZYVA® (obinutuzumab) or rituximab are administered intravenously in addition to the daily VENCLEXTA pills.

GAZYVA and rituximab are a type of antibody therapy that targets and attaches to the CD20 protein found on the surface of CLL cells as well as some healthy blood cells. Once attached to the CD20 protein, GAZYVA and rituximab are thought to work in different ways, such as:

  • By destroying the cancer cells directly
  • By helping your own immune system destroy the cancer cells

VENCLEXTA regimens for previously untreated CLL/SLL are designed to be completed in a set amount of time (12 months when combined with GAZYVA or 14 months when combined with acalabrutinib).

Treatment Guide

Actor portrayals.

Actor portrayals.

Patient Brochure

Learn more about what VENCLEXTA can offer

Sign up for more info on VENCLEXTA,
including tools and resources to help you
make an informed treatment decision.